Bayer eyes wider use for Xarelto with new trials
FRANKFURT (Reuters) – Bayer has initiated two new late-stage studies to widen the use of its anti-blood-clotting pill Xarelto, one of its most important new drugs. The German company, which is developing the pill with U. S. peer Johnson & Johnson, said it would start a Phase III clinical trial to test Xarelto in patients with chronic heart failure and significant coronary artery disease. . . .
View full post on Health News Headlines – Yahoo! News
Leave a Reply